GlobeNewswire by notified

IBT förvärvar probiotisk läkemedelsplattform som kan förebygga antibiotikaresistenta sjukhusinfektioner

Dela

På grund av företagets unika kompetens inom utveckling av probiotiska läkemedel har Infant Bacterial Therapeutics AB (IBT) erhållit en exklusiv global licens från Medical College of Wisconsin (MCW) till en teknologiplattform bestående av genetiskt modifierade bakterier. IBT kommer att undersöka hur man utvecklar ett probiotiskt läkemedel baserat på denna plattform för att förebygga det växande problemet med sjukhusförvärvade infektioner vilka orsakar hög sjuk- och dödlighet.

Antibiotikaresistens har ökat till farliga nivåer över hela världen, inklusive sjukhusförvärvade infektioner orsakade av vankomycinresistenta enterokocker (VRE). VRE-infektioner har blivit en allvarlig folkhälsoutmaning kopplad till komplexiteten av antibiotikaresistens, vilket resulterat i 54 000 sjukdomsfall och 5 000 dödsfall bland inlagda patienter enbart i USA. VRE-infektioner beräknas orsaka årliga sjukvårdskostnader i USA för 539 miljoner dollar.

"Vi undersöker nu om, och i så fall hur, vi kan bidra till vården av dessa patienter genom en alternativ väg för att undvika ytterligare antibiotikaresistens. Denna nya möjlighet bygger på vårt nuvarande fokus på IBP-9414, som kvarstår, och drar nytta av den ledande expertis vi etablerat de senaste 10 åren inom probiotika med farmaceutisk kvalitet. Vår förväntning är att slutföra IBP-9414-rekryteringen med befintligt kapital och utforskar samtidigt denna nya plattform med minimal finansiell exponering”, säger Staffan Strömberg, vd, IBT.

"Kombinationen av MCW:s teknologi och IBT:s expertis att utveckla bakteriebaserade terapier ger unika nya möjligheter att bekämpa sjukhusförvärvade infektioner. Detta projekt är ett exempel på MCW:s engagemang att omsätta vår kunskap till innovativ patientvård samt vår strävan mot en hälsosammare värld. Vi ser fram emot IBT:s vidareutveckling av denna bakteriella teknologi som uppfanns av Drs. Nita Salzman, Chris Kristich och Sushma Kommineni på avdelningarna för Pediatrik och Mikrobiologi & Immunologi här på MCW”, säger Ann Nattinger, MD, MPH, MACP, Associate for Research vid MCW.

För ytterligare information vänligen kontakta
Staffan Strömberg, verkställande direktör

Offentliggörande

Denna information är sådan information som IBT (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 2023-01-12 10:10 CET.

Bilagor

För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.
För att se det här innehållet från ml-eu.globenewswire.com måste du ge ditt medgivande sidans topp.

Om

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire by notified

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire by notified

Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease8.2.2023 22:01:00 CET | Press release

The two induction cohorts missed the co-primary endpoints of clinical remission and endoscopic response at Week 10In the maintenance phase, filgotinib 200mg once daily achieved the co-primary endpoints of clinical remission and endoscopic response at Week 58The safety findings were generally consistent with the known profile of filgotinib in rheumatoid arthritis (RA) and ulcerative colitis (UC)Galapagos decided not to submit a Marketing Authorization Application in Europe based on these topline dataGalapagos remains fully committed to filgotinib, a JAK1 preferential inhibitor orally administered once daily, and its approved indications, RA and UC, and is on track to start a Phase 3 trial in axial spondyloarthritis (AxSpA) later this year Mechelen, Belgium; 8February2023, 22:01CET; regulated information; Galapagos NV (Euronext & NASDAQ: GLPG) todayannouncedthe topline results from DIVERSITY,a global Phase 3 trial to evaluate the safety and efficacy of filgotinib,100mg or 200mg once dail

X8 AG Submits a Swiss Fintech Licence Application8.2.2023 21:21:16 CET | Press release

X8 AG submitted the application for a Swiss FinTech license according to Art. 1b Banking Act with the intention of operating a regulated global stablecoin system BAAR, Switzerland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The X8 AG team has successfully submitted the application to FINMA, the Swiss Financial Market Supervisory Authority, for the Swiss FinTech license according to Article 1b Banking Act. This marks an important step for X8 AG on its way to become a fully regulated global stablecoin system and significantly differentiating itself from the current non-regulated crypto space. Switzerland offers one of the most advanced regulatory frameworks for digital assets. X8 AG believes that designing its stablecoin system under Swiss law is the best starting point to achieve a global X8 cross-border framework for payments. Full compliance with the Swiss regulatory framework strengthens the high standards of protection for clients. X8 AG aims to empower users and their money with frictionles

GN Store Nord announces intention to initiate a rights issue8.2.2023 20:08:16 CET | Press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL This announcement does not constitute an offering memorandum or a prospectus as defined by Regulation (EU) No. 2017/1129 of 14 June 2017. The offer to acquire securities pursuant to the offering is made, and any investor should make their investment decision, solely on the basis of information that is contained in the prospectus to be made generally available in Denmark in connection with the offering. GN Store Nord announces intention to initiate a rights issue In accordance with our announcement on November 11, 2022, GN has conducted a comprehensive review of the appropriate capital structure. In light of the current macroeconomic environment and GN’s leverage, GN announces today that it intends to raise gross proceeds of DKK 7 billion in the first half

Nokia Corporation: Repurchase of own shares on 08.02.20238.2.2023 20:00:00 CET | Press release

Nokia Corporation Stock Exchange Release 8 February 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 08.02.2023 Espoo, Finland – On 8 February 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL282,2294.39CEUX20,3804.39AQEU6,3784.39TQEX5,0134.38Total314,0004.39 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023

Interim report 2022/23 - 15% revenue growth and DKK 145 million operating profit (+25%) for the first half following a challenging second quarter8.2.2023 18:57:07 CET | Press release

ANNOUNCEMENT NO. 234 9 February 2023 Interim report for the first half of 2022/23 15% revenue growth and DKK 145 million operating profit (+25%) for the first half following a challenging second quarter Steen Søndergaard, CEO: “Following a very satisfactory 2021/22 with historically high revenue and operating profit growth rates, revenue for the first half of 2022/23 unfortunately disappointed, despite 15% growth. Second quarter sales of instruments, particularly in the North American market, were challenged by a generally more subdued investment sentiment in our primary business segment, cell-based therapy. Our order intake was mainly impacted by weakened demand from capital-sensitive development companies. On the other hand, we saw continued satisfactory growth in sales of consumables and services. Despite the unfavourable market conditions, our earnings continued to grow. While our market is currently affected by the prevailing macroeconomic environment, we have a strong underlying